CDK4 and neoplasm: To do this, we carried out evolutionary analysis (tumor phylogeny, clonal dynamics) to identify acquired or enriched genomic alterations in the trial baseline sample(s) (which are post-CDK4/6i) as compared to the older, pre- CDK4/6i sample (Figs. 5 and 6).